| 标题 |
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. PMID: 35644155. |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
大力的冬萱
ale
认真的不评
Nexus
arniu2008
Copyright
yjh123
俊秀的白曼
关山北
Nole
可靠的南露
行走的荷尔蒙
殷勤的紫槐
dawd
aaaa
蓝天
sagitar
挖掘机
皖公网安备34019202002308
